Hansoh Pharmaceutical Group Company Limited
3692
Rang în acțiuni
#905
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Preț acțiune
$4.40
Capitalizare de piață
$26.66B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
-4.79%
Țară
CN
Tranzacționează Hansoh Pharmaceutical Group Company Limited (3692)
Categorie
Healthcare
Raport P/B pentru Hansoh Pharmaceutical Group Company Limited (3692)
Raport P/B la data de October 2026 TTM: 4.30
Conform celor mai recente rapoarte financiare și prețului acțiunilor Hansoh Pharmaceutical Group Company Limited, raportul P/B actual (TTM) este 4.30. La sfârșitul anului 2023, compania avea un P/B de 3.47.
Istoricul raportului P/B pentru Hansoh Pharmaceutical Group Company Limited din 2016 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| 2026 (TTM) | 4.30 | 28.00% |
| 2024 | 3.36 | -3.35% |
| 2023 | 3.47 | 1.44% |
| 2022 | 3.42 | -25.17% |
| 2021 | 4.57 | -56.01% |
| 2020 | 10.40 | 7.03% |
| 2019 | 9.72 | -86.95% |
| 2018 | 74.45 | 213.64% |
| 2017 | 23.74 | -55.98% |
| 2016 | 53.92 | 0.00% |
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | 17.21% |
IN
|
